公开(公告)号：WO2019036086A1

公开(公告)日：2019-02-21

申请号：PCT/US2018/035830

申请日：2018-06-04

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

发明人： OLSON, Eric N. ,  ZHOU, Huanyu ,  BASSEL-DUBY, Rhonda

IPC分类号： C12N5/07 ,  C12N5/074 ,  C07K14/47 ,  A61K38/18

CPC分类号： C07K14/4702 ,  A61K38/1709 ,  C12N5/0657 ,  C12N2506/1307

摘要： The present disclosure involves the use of reprogramming factors including AKT1, GATA4, TBX5, MEF2C, HAND2 and either ZNF281 or ASCLl to reprogram adult non- cardiomyocytes, such as cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair.

公开(公告)号：WO2023077052A1

公开(公告)日：2023-05-04

申请号：PCT/US2022/078854

申请日：2022-10-28

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

发明人： GARRY, Glynnis ,  ZHOU, Huanyu ,  OLSON, Eric

IPC分类号： A61K38/17 ,  A61K38/18 ,  C07K14/47 ,  C12N5/07

摘要： The present disclosure involves the use of the reprogramming factor PHF7, and optionally further using TBX5, MEF2C, GATA4, HAND2, MYCD, and/or phosphorylated AKT1 to reprogram adult non-cardiomyocytes, such as cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo in adult human and murine models of myocardial infarction and/or heart failure. Such methods find particular use in the treatment of patients'post-myocardial infarction and/or heart failure to prevent, limit, or reverse scarring and to promote myocardial repair.